ADAR1 Capital Management »

89bio shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of 89bio (ETNB) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in 89bio

Tip: Access up to 7 years of quarterly data

All positions including 89bio held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 89bio by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $36k 3.1k 11.64
2023-12-31 $4.8k 430 11.17

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding 89bio

RA Capital Management
Henderson Group
Suvretta Capital Management
BlackRock
BlackRock
BVF
Vanguard Group
Pictet Asset Management Holding SA
State Street Corporation
Westfield Capital Management Company
Citadel Advisors
Deep Track Capital
Geode Capital Management
Redmile Group
MPM Oncology Impact Management

View all funds holding 89bio